News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
543,222 Results
Type
Article (45055)
Company Profile (118)
Press Release (498049)
Multimedia
Podcasts (80)
Webinars (11)
Section
Business (149076)
Career Advice (2401)
Deals (28351)
Drug Delivery (121)
Drug Development (69681)
Employer Resources (151)
FDA (16033)
Job Trends (12067)
News (270553)
Policy (30013)
Tag
2024 BioCapital Digital (5)
2024 BioForest Digital (2)
2024 BioForest Standard (1)
2024 BioMidwest Digital (2)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (1)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (9)
2024 Biotech Beach Digital (3)
2024 Biotech Beach Standard (4)
2024 Genetown Standard (4)
2024 Lone Star Bio Digital (1)
2024 Pharm Country Digital (3)
2024 Pharm Country Standard (3)
2025 Lone Star Bio Digital (3)
2026 BioCapital Elite (1)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (2)
2026 Bio NC Standard (1)
2026 Biotech Bay Elite (1)
2026 Biotech Beach Elite (2)
2026 Genetown Elite (3)
2026 Genetown Standard (1)
2026 Pharm Country Elite (1)
2026 Pharm Country Standard (2)
Academia (2310)
Academic (1)
Accelerated approval (6)
Adcomms (29)
Allergies (77)
Alliances (37734)
ALS (86)
Alzheimer's disease (1430)
Antibody-drug conjugate (ADC) (127)
Approvals (15989)
Artificial intelligence (236)
Autoimmune disease (26)
Automation (11)
Bankruptcy (317)
Best Places to Work (9253)
BIOSECURE Act (22)
Biosimilars (113)
Biotechnology (70)
Bladder cancer (66)
Brain cancer (26)
Breast cancer (252)
Cancer (1991)
Cardiovascular disease (181)
Career advice (2006)
Career pathing (32)
CAR-T (142)
Cell therapy (399)
Cervical cancer (19)
Clinical research (56576)
Collaboration (690)
Compensation (515)
Complete response letters (29)
COVID-19 (2603)
CRISPR (41)
C-suite (209)
Cystic fibrosis (94)
Data (1891)
Decentralized trials (2)
Denatured (14)
Depression (50)
Diabetes (258)
Diagnostics (5318)
Digital health (15)
Diversity (4)
Diversity, equity & inclusion (42)
Drug discovery (100)
Drug pricing (119)
Drug shortages (30)
Duchenne muscular dystrophy (95)
Earnings (59870)
Editorial (43)
Employer branding (20)
Employer resources (136)
Events (78544)
Executive appointments (635)
FDA (17211)
Featured Employer (33)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (6)
Funding (619)
Gene editing (102)
Generative AI (22)
Gene therapy (299)
GLP-1 (783)
Government (3899)
Grass and pollen (5)
Guidances (46)
Healthcare (14920)
Huntington's disease (24)
IgA nephropathy (26)
Immunology and inflammation (133)
Indications (24)
Infectious disease (2747)
Inflammatory bowel disease (127)
Inflation Reduction Act (9)
Influenza (48)
Intellectual property (84)
Interviews (449)
IPO (14044)
IRA (48)
Job creations (3197)
Job search strategy (1667)
Kidney cancer (10)
Labor market (30)
Layoffs (506)
Leadership (20)
Legal (7039)
Liver cancer (70)
Lung cancer (284)
Lymphoma (137)
Machine learning (5)
Management (51)
Manufacturing (280)
MASH (67)
Medical device (11327)
Medtech (11330)
Mergers & acquisitions (14793)
Metabolic disorders (707)
Multiple sclerosis (72)
NASH (22)
Neurodegenerative disease (93)
Neuropsychiatric disorders (31)
Neuroscience (1939)
NextGen: Class of 2025 (5012)
Non-profit (3180)
Northern California (2354)
Now hiring (16)
Obesity (396)
Opinion (217)
Ovarian cancer (66)
Pain (81)
Pancreatic cancer (75)
Parkinson's disease (145)
Partnered (16)
Patents (224)
Patient recruitment (93)
Peanut (44)
People (43469)
Pharmaceutical (34)
Pharmacy benefit managers (21)
Phase I (16908)
Phase II (24494)
Phase III (20041)
Pipeline (1111)
Policy (158)
Postmarket research (2286)
Preclinical (6900)
Press Release (30)
Prostate cancer (98)
Psychedelics (35)
Radiopharmaceuticals (210)
Rare diseases (388)
Real estate (4378)
Recruiting (60)
Regulatory (21184)
Reports (31)
Research institute (2067)
Resumes & cover letters (401)
Rett syndrome (4)
RNA editing (3)
RSV (47)
Schizophrenia (73)
Series A (118)
Series B (77)
Service/supplier (9)
Sickle cell disease (54)
Southern California (1989)
Special edition (16)
Spinal muscular atrophy (129)
Sponsored (32)
Startups (2865)
State (1)
Stomach cancer (16)
Supply chain (70)
Tariffs (32)
The Weekly (65)
United States (19867)
Vaccines (748)
Venture capitalists (40)
Weight loss (291)
Women's health (31)
Worklife (19)
Date
Today (101)
Last 7 days (423)
Last 30 days (2206)
Last 365 days (29855)
2025 (8835)
2024 (31526)
2023 (35125)
2022 (45213)
2021 (48734)
2020 (45737)
2019 (36456)
2018 (27644)
2017 (28064)
2016 (26021)
2015 (28345)
2014 (22072)
2013 (18002)
2012 (19324)
2011 (19995)
2010 (18443)
Location
Africa (681)
Alabama (40)
Alaska (6)
Arizona (171)
Arkansas (10)
Asia (31588)
Australia (5625)
California (5280)
Canada (1490)
China (398)
Colorado (228)
Connecticut (260)
Delaware (131)
Europe (76967)
Florida (810)
Georgia (180)
Hawaii (1)
Idaho (37)
Illinois (428)
India (23)
Indiana (238)
Iowa (10)
Japan (138)
Kansas (82)
Kentucky (13)
Louisiana (6)
Maine (61)
Maryland (815)
Massachusetts (3996)
Michigan (180)
Minnesota (316)
Mississippi (1)
Missouri (68)
Montana (12)
Nebraska (19)
Nevada (53)
New Hampshire (50)
New Jersey (1526)
New Mexico (15)
New York (1487)
North Carolina (875)
North Dakota (6)
Northern California (2354)
Ohio (157)
Oklahoma (9)
Oregon (28)
Pennsylvania (1156)
Puerto Rico (9)
Rhode Island (20)
South America (1045)
South Carolina (18)
South Dakota (1)
Southern California (1989)
Tennessee (84)
Texas (748)
Utah (140)
Virginia (123)
Washington D.C. (58)
Washington State (490)
West Virginia (3)
Wisconsin (50)
543,222 Results for "edap tms s a".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
EDAP Appoints Glen French to Board of Directors
March 4, 2025
·
5 min read
Press Releases
EDAP Reports Record HIFU Fourth Quarter and Full-Year 2024 Results
March 28, 2025
·
21 min read
Business
EDAP Reports First Quarter 2024 Financial Results
EDAP TMS SA, the global leader in robotic energy-based therapies, reported unaudited financial results for the first quarter of 2024.
May 16, 2024
·
15 min read
Business
EDAP Appoints New Executive Leaders to Strengthen Europe and Middle East Commercial Operations
EDAP TMS SA, the global leader in robotic energy-based therapies, announced the appointments of Damien Desmedt and Alexander Fromm to further strengthen the Company’s European and Middle Eastern commercial leadership.
June 3, 2024
·
6 min read
Business
EDAP Reports Fourth Quarter and Full-Year 2023 Financial Results
EDAP TMS SA, the global leader in robotic energy-based therapies, reported unaudited financial results for the fourth quarter and full-year 2023.
March 27, 2024
·
19 min read
Business
EDAP to Announce First Quarter 2024 Financial Results on May 16, 2024
EDAP TMS SA, the global leader in robotic energy-based therapies, announced that it will release its financial results for the first quarter ended March 31, 2024, before the markets open on Thursday, May 16th, 2024.
May 2, 2024
·
1 min read
Business
EDAP Appoints Lance Willsey, M.S., M.D. to Board of Directors
EDAP TMS SA, the global leader in robotic energy-based therapies, announced the appointment of Lance Willsey, M.S., M.D. to its Board of Directors.
December 6, 2023
·
3 min read
Press Releases
EDAP Announces First Pancreatic Cancer Patient Treated with Proprietary HIFU Technology
January 9, 2025
·
6 min read
EDAP Announces FDA Breakthrough Device Designation for Focal One® in the Treatment of Deep Infiltrating Rectal Endometriosis
EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, announced today that its Focal One platform has been granted Breakthrough Device designation by the US Food and Drug Administration (FDA) for the treatment of deep infiltrating endometriosis (DIE).
March 4, 2024
·
7 min read
Business
EDAP to Announce Fourth Quarter and Full-Year 2023 Financial Results on March 27, 2024
EDAP TMS SA, the global leader in robotic energy-based therapies, announced that it will release its financial results for the fourth quarter and full-year ended December 31, 2023, before the markets open on Wednesday, March 27th, 2024.
March 13, 2024
·
1 min read
1 of 54,323
Next
